Amyloid beta peptide is an important biomarker in Alzheimer's disease, with the
amyloidogenic hypothesis as one of the central hypotheses trying to explain this type of …

The promise of nicotinic receptors as a therapeutic target has yet to be fully realized, despite
solid data supporting their involvement in neurological and neuropsychiatric diseases. The …

According to the facts and figures 2023 on Alzheimer's disease (AD) stated that 6.7 million
Americans over the age of 65 have AD. The scenario of AD has reached up to the maximum …

Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions worldwide. One
of the leading hypotheses for the underlying cause of AD is a reduction in nicotinic receptor …

Alzheimer disease is one of the most challenging demons in our society due to its very high
prevalence and its clinical manifestations which cause deterioration of cognition …

Phage display is a molecular biology technique that allows the presentation of foreign
peptides on the surface of bacteriophages. It is widely utilized for applications such as the …

The strong association between hearing loss and cognitive decline has developed into a
major health challenge that calls for early detection, diagnosis and prevention. Hearing loss …

Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat
Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in …

Alzheimer disease (AD) is advanced neurodegenerative condition characterized by
dementia, accounting for an estimated 60%–70% of cases worldwide. AD is progressive …

Background. At least 55 million individuals suffer from dementia globally, of which
Alzheimer's disease (AD) accounts for 60–70% of cases. Alzheimer's disease is the only …